ES2222748T3 - Utilizacion de heparinas de bajo peso molecular para la prevencion y/o el tratamiento de enfermedades motoneuronales. - Google Patents

Utilizacion de heparinas de bajo peso molecular para la prevencion y/o el tratamiento de enfermedades motoneuronales.

Info

Publication number: ES2222748T3
Authority: ES; Spain
Prior art keywords: accordance; low weight; weight heparin; molecular; heparin molecular
Prior art date: 1998-12-17
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Lifetime

Application number

ES99958308T

Other languages

English (en)

Spanish (es)

Inventor

Jean-Marie Stutzmann

Andre Uzan

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Aventis Pharma SA

Original Assignee

Aventis Pharma SA

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-12-17

Filing date

1999-12-13

Publication date

2005-02-01

1999-12-13 Application filed by Aventis Pharma SA filed Critical Aventis Pharma SA

2005-02-01 Application granted granted Critical

2005-02-01 Publication of ES2222748T3 publication Critical patent/ES2222748T3/es

2019-12-13 Anticipated expiration legal-status Critical

Status Expired - Lifetime legal-status Critical Current

Links

229920000669 heparin Polymers 0.000 title claims description 42
229960002897 heparin Drugs 0.000 title claims description 35
230000002265 prevention Effects 0.000 title claims description 9
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims description 8
201000010099 disease Diseases 0.000 title claims description 7
230000001095 motoneuron effect Effects 0.000 title 1
208000005264 motor neuron disease Diseases 0.000 claims abstract description 8
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims description 60
229960000610 enoxaparin Drugs 0.000 claims description 18
210000002569 neuron Anatomy 0.000 claims description 10
201000010901 lateral sclerosis Diseases 0.000 claims description 6
239000003814 drug Substances 0.000 claims description 5
206010003694 Atrophy Diseases 0.000 claims description 3
239000002253 acid Substances 0.000 claims description 3
230000037444 atrophy Effects 0.000 claims description 3
-1 heparin ester Chemical class 0.000 claims description 3
210000003205 muscle Anatomy 0.000 claims description 3
229940090880 ardeparin Drugs 0.000 claims description 2
229940107792 certoparin Drugs 0.000 claims description 2
229960004969 dalteparin Drugs 0.000 claims description 2
229960003828 danaparoid Drugs 0.000 claims description 2
XEKSTYNIJLDDAZ-JASSWCPGSA-D decasodium;(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5r,6r)-6-[(2r,3s,4s,5r,6r)-2-carboxylato-4-hydroxy-6-[(2r,3s,4r,5r,6s)-4-hydroxy-6-methoxy-5-(sulfonatoamino)-2-(sulfonatooxymethyl)oxan-3-yl]oxy-5-sulfonatooxyoxan-3-yl]oxy-5-(sulfonatoamino)-4-sulfonatooxy-2-(sul Chemical compound [Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].O[C@@H]1[C@@H](NS([O-])(=O)=O)[C@@H](OC)O[C@H](COS([O-])(=O)=O)[C@H]1O[C@H]1[C@H](OS([O-])(=O)=O)[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](OS([O-])(=O)=O)[C@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O[C@@H]4[C@@H]([C@@H](O)[C@H](O)[C@@H](COS([O-])(=O)=O)O4)NS([O-])(=O)=O)[C@H](O3)C([O-])=O)O)[C@@H](COS([O-])(=O)=O)O2)NS([O-])(=O)=O)[C@H](C([O-])=O)O1 XEKSTYNIJLDDAZ-JASSWCPGSA-D 0.000 claims description 2
229960000899 nadroparin Drugs 0.000 claims description 2
229920001542 oligosaccharide Polymers 0.000 claims description 2
150000002482 oligosaccharides Chemical class 0.000 claims description 2
229960004762 parnaparin Drugs 0.000 claims description 2
238000002360 preparation method Methods 0.000 claims description 2
201000008752 progressive muscular atrophy Diseases 0.000 claims description 2
229960005062 tinzaparin Drugs 0.000 claims description 2
229960005496 reviparin Drugs 0.000 claims 1
229940127215 low-molecular weight heparin Drugs 0.000 abstract description 10
239000003055 low molecular weight heparin Substances 0.000 abstract description 6
210000002161 motor neuron Anatomy 0.000 description 27
210000001130 astrocyte Anatomy 0.000 description 14
210000004027 cell Anatomy 0.000 description 12
230000000694 effects Effects 0.000 description 11
239000000203 mixture Substances 0.000 description 11
239000002609 medium Substances 0.000 description 8
230000001228 trophic effect Effects 0.000 description 8
NCGICGYLBXGBGN-UHFFFAOYSA-N 3-morpholin-4-yl-1-oxa-3-azonia-2-azanidacyclopent-3-en-5-imine;hydrochloride Chemical compound Cl.[N-]1OC(=N)C=[N+]1N1CCOCC1 NCGICGYLBXGBGN-UHFFFAOYSA-N 0.000 description 6
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
210000000278 spinal cord Anatomy 0.000 description 5
230000004083 survival effect Effects 0.000 description 5
229940079593 drug Drugs 0.000 description 4
238000000034 method Methods 0.000 description 4
239000011734 sodium Substances 0.000 description 4
239000011780 sodium chloride Substances 0.000 description 4
241000283690 Bos taurus Species 0.000 description 3
108091003079 Bovine Serum Albumin Proteins 0.000 description 3
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
229940098773 bovine serum albumin Drugs 0.000 description 3
239000003085 diluting agent Substances 0.000 description 3
238000005194 fractionation Methods 0.000 description 3
210000002241 neurite Anatomy 0.000 description 3
XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
102000004219 Brain-derived neurotrophic factor Human genes 0.000 description 2
108090000715 Brain-derived neurotrophic factor Proteins 0.000 description 2
101100283604 Caenorhabditis elegans pigk-1 gene Proteins 0.000 description 2
MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
208000032319 Primary lateral sclerosis Diseases 0.000 description 2
RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
102000004142 Trypsin Human genes 0.000 description 2
108090000631 Trypsin Proteins 0.000 description 2
206010046298 Upper motor neurone lesion Diseases 0.000 description 2
239000002671 adjuvant Substances 0.000 description 2
206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 2
239000007864 aqueous solution Substances 0.000 description 2
239000002775 capsule Substances 0.000 description 2
238000005119 centrifugation Methods 0.000 description 2
238000003501 co-culture Methods 0.000 description 2
238000010494 dissociation reaction Methods 0.000 description 2
230000005593 dissociations Effects 0.000 description 2
210000002257 embryonic structure Anatomy 0.000 description 2
150000002148 esters Chemical class 0.000 description 2
239000001963 growth medium Substances 0.000 description 2
230000023597 hemostasis Effects 0.000 description 2
239000003701 inert diluent Substances 0.000 description 2
238000002347 injection Methods 0.000 description 2
239000007924 injection Substances 0.000 description 2
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
238000002483 medication Methods 0.000 description 2
201000000585 muscular atrophy Diseases 0.000 description 2
239000008363 phosphate buffer Substances 0.000 description 2
230000000750 progressive effect Effects 0.000 description 2
KIDHWZJUCRJVML-UHFFFAOYSA-N putrescine Chemical compound NCCCCN KIDHWZJUCRJVML-UHFFFAOYSA-N 0.000 description 2
210000002966 serum Anatomy 0.000 description 2
239000002356 single layer Substances 0.000 description 2
229910052708 sodium Inorganic materials 0.000 description 2
239000008247 solid mixture Substances 0.000 description 2
239000003381 stabilizer Substances 0.000 description 2
UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
239000000126 substance Substances 0.000 description 2
238000003786 synthesis reaction Methods 0.000 description 2
239000012588 trypsin Substances 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
241000283707 Capra Species 0.000 description 1
UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
102000016911 Deoxyribonucleases Human genes 0.000 description 1
108010053770 Deoxyribonucleases Proteins 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
208000032843 Hemorrhage Diseases 0.000 description 1
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
102000004877 Insulin Human genes 0.000 description 1
108090001061 Insulin Proteins 0.000 description 1
102100024392 Insulin gene enhancer protein ISL-1 Human genes 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
235000019687 Lamb Nutrition 0.000 description 1
BAQCROVBDNBEEB-UBYUBLNFSA-N Metrizamide Chemical compound CC(=O)N(C)C1=C(I)C(NC(C)=O)=C(I)C(C(=O)N[C@@H]2[C@H]([C@H](O)[C@@H](CO)OC2O)O)=C1I BAQCROVBDNBEEB-UBYUBLNFSA-N 0.000 description 1
206010028289 Muscle atrophy Diseases 0.000 description 1
108010025020 Nerve Growth Factor Proteins 0.000 description 1
102000007072 Nerve Growth Factors Human genes 0.000 description 1
IOVCWXUNBOPUCH-UHFFFAOYSA-N Nitrous acid Chemical compound ON=O IOVCWXUNBOPUCH-UHFFFAOYSA-N 0.000 description 1
239000005662 Paraffin oil Substances 0.000 description 1
229930040373 Paraformaldehyde Natural products 0.000 description 1
229930182555 Penicillin Natural products 0.000 description 1
JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
239000005700 Putrescine Substances 0.000 description 1
108010071390 Serum Albumin Proteins 0.000 description 1
102000007562 Serum Albumin Human genes 0.000 description 1
CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
238000000692 Student's t-test Methods 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
208000007536 Thrombosis Diseases 0.000 description 1
108091023040 Transcription factor Proteins 0.000 description 1
102000040945 Transcription factor Human genes 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
238000001042 affinity chromatography Methods 0.000 description 1
150000008044 alkali metal hydroxides Chemical class 0.000 description 1
239000000908 ammonium hydroxide Substances 0.000 description 1
125000000129 anionic group Chemical group 0.000 description 1
230000001858 anti-Xa Effects 0.000 description 1
230000006907 apoptotic process Effects 0.000 description 1
238000013459 approach Methods 0.000 description 1
229910052786 argon Inorganic materials 0.000 description 1
229960005070 ascorbic acid Drugs 0.000 description 1
235000010323 ascorbic acid Nutrition 0.000 description 1
239000011668 ascorbic acid Substances 0.000 description 1
239000002585 base Substances 0.000 description 1
238000007068 beta-elimination reaction Methods 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
239000011575 calcium Substances 0.000 description 1
239000006285 cell suspension Substances 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
239000013043 chemical agent Substances 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
238000000576 coating method Methods 0.000 description 1
229940110456 cocoa butter Drugs 0.000 description 1
235000019868 cocoa butter Nutrition 0.000 description 1
230000007850 degeneration Effects 0.000 description 1
125000000600 disaccharide group Chemical group 0.000 description 1
BVTBRVFYZUCAKH-UHFFFAOYSA-L disodium selenite Chemical compound [Na+].[Na+].[O-][Se]([O-])=O BVTBRVFYZUCAKH-UHFFFAOYSA-L 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
239000002270 dispersing agent Substances 0.000 description 1
239000008298 dragée Substances 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
230000002255 enzymatic effect Effects 0.000 description 1
230000003203 everyday effect Effects 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
239000003889 eye drop Substances 0.000 description 1
229940012356 eye drops Drugs 0.000 description 1
230000001605 fetal effect Effects 0.000 description 1
238000001914 filtration Methods 0.000 description 1
235000003599 food sweetener Nutrition 0.000 description 1
210000000609 ganglia Anatomy 0.000 description 1
238000002523 gelfiltration Methods 0.000 description 1
230000002518 glial effect Effects 0.000 description 1
239000008103 glucose Substances 0.000 description 1
150000004676 glycans Chemical class 0.000 description 1
125000005456 glyceride group Chemical group 0.000 description 1
239000008187 granular material Substances 0.000 description 1
230000009036 growth inhibition Effects 0.000 description 1
239000001257 hydrogen Substances 0.000 description 1
229910052739 hydrogen Inorganic materials 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
238000011534 incubation Methods 0.000 description 1
229940125396 insulin Drugs 0.000 description 1
108010090448 insulin gene enhancer binding protein Isl-1 Proteins 0.000 description 1
230000000968 intestinal effect Effects 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
235000015110 jellies Nutrition 0.000 description 1
239000008274 jelly Substances 0.000 description 1
239000008101 lactose Substances 0.000 description 1
239000007788 liquid Substances 0.000 description 1
239000006210 lotion Substances 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
238000012423 maintenance Methods 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
210000002418 meninge Anatomy 0.000 description 1
229960000554 metrizamide Drugs 0.000 description 1
230000000877 morphologic effect Effects 0.000 description 1
239000002324 mouth wash Substances 0.000 description 1
210000004400 mucous membrane Anatomy 0.000 description 1
230000020763 muscle atrophy Effects 0.000 description 1
239000007923 nasal drop Substances 0.000 description 1
229940100662 nasal drops Drugs 0.000 description 1
239000007922 nasal spray Substances 0.000 description 1
230000032405 negative regulation of neuron apoptotic process Effects 0.000 description 1
210000005036 nerve Anatomy 0.000 description 1
210000005044 neurofilament Anatomy 0.000 description 1
239000003900 neurotrophic factor Substances 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
239000003921 oil Substances 0.000 description 1
229920002866 paraformaldehyde Polymers 0.000 description 1
229940049954 penicillin Drugs 0.000 description 1
KHIWWQKSHDUIBK-UHFFFAOYSA-N periodic acid Chemical compound OI(=O)(=O)=O KHIWWQKSHDUIBK-UHFFFAOYSA-N 0.000 description 1
150000002978 peroxides Chemical class 0.000 description 1
CMFNMSMUKZHDEY-UHFFFAOYSA-N peroxynitrous acid Chemical compound OON=O CMFNMSMUKZHDEY-UHFFFAOYSA-N 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
239000006187 pill Substances 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
229920001282 polysaccharide Polymers 0.000 description 1
239000005017 polysaccharide Substances 0.000 description 1
235000015277 pork Nutrition 0.000 description 1
239000000843 powder Substances 0.000 description 1
239000000047 product Substances 0.000 description 1
229960003387 progesterone Drugs 0.000 description 1
239000000186 progesterone Substances 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
108090000623 proteins and genes Proteins 0.000 description 1
230000002685 pulmonary effect Effects 0.000 description 1
150000003242 quaternary ammonium salts Chemical class 0.000 description 1
230000008929 regeneration Effects 0.000 description 1
238000011069 regeneration method Methods 0.000 description 1
239000011347 resin Substances 0.000 description 1
229920005989 resin Polymers 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
239000000377 silicon dioxide Substances 0.000 description 1
235000017557 sodium bicarbonate Nutrition 0.000 description 1
229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
229960001471 sodium selenite Drugs 0.000 description 1
235000015921 sodium selenite Nutrition 0.000 description 1
239000011781 sodium selenite Substances 0.000 description 1
239000000243 solution Substances 0.000 description 1
239000002904 solvent Substances 0.000 description 1
208000002320 spinal muscular atrophy Diseases 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
238000007619 statistical method Methods 0.000 description 1
230000001954 sterilising effect Effects 0.000 description 1
238000004659 sterilization and disinfection Methods 0.000 description 1
239000003206 sterilizing agent Substances 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
229960005322 streptomycin Drugs 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
239000000829 suppository Substances 0.000 description 1
239000000725 suspension Substances 0.000 description 1
239000003765 sweetening agent Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
239000006188 syrup Substances 0.000 description 1
238000012353 t test Methods 0.000 description 1
239000003826 tablet Substances 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
238000012360 testing method Methods 0.000 description 1
239000002562 thickening agent Substances 0.000 description 1
230000009424 thromboembolic effect Effects 0.000 description 1
238000011200 topical administration Methods 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
238000001665 trituration Methods 0.000 description 1
239000002966 varnish Substances 0.000 description 1
235000013311 vegetables Nutrition 0.000 description 1
238000005406 washing Methods 0.000 description 1
239000000080 wetting agent Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/727—Heparin; Heparan
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Epidemiology (AREA)
Dermatology (AREA)
Molecular Biology (AREA)
Heart & Thoracic Surgery (AREA)
Hospice & Palliative Care (AREA)
Urology & Nephrology (AREA)
Cardiology (AREA)
Vascular Medicine (AREA)
Psychiatry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Polysaccharides And Polysaccharide Derivatives (AREA)
External Artificial Organs (AREA)

ES99958308T 1998-12-17 1999-12-13 Utilizacion de heparinas de bajo peso molecular para la prevencion y/o el tratamiento de enfermedades motoneuronales. Expired - Lifetime ES2222748T3 (es)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
FR9815919A FR2787329B1 (fr)	1998-12-17	1998-12-17	Nouvelle application therapeutique des heparines de bas poids moleculaire
FR9815919		1998-12-17

Publications (1)

Publication Number	Publication Date
ES2222748T3 true ES2222748T3 (es)	2005-02-01

Family

ID=9534065

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ES99958308T Expired - Lifetime ES2222748T3 (es)	1998-12-17	1999-12-13	Utilizacion de heparinas de bajo peso molecular para la prevencion y/o el tratamiento de enfermedades motoneuronales.

Country Status (15)

Country	Link
US (4)	US20020040013A1 (de)
EP (1)	EP1140119B1 (de)
JP (1)	JP2002532431A (de)
AT (1)	ATE273711T1 (de)
AU (1)	AU1569700A (de)
CA (1)	CA2354762C (de)
DE (1)	DE69919578T2 (de)
DK (1)	DK1140119T3 (de)
ES (1)	ES2222748T3 (de)
FR (1)	FR2787329B1 (de)
IL (2)	IL143279A0 (de)
NO (1)	NO20012849L (de)
PT (1)	PT1140119E (de)
SI (1)	SI1140119T1 (de)
WO (1)	WO2000035462A1 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP4897991B2 (ja) *	1999-07-23	2012-03-14	ラボラトリオスファルマセウティコスロビソシエダッドアノニマ	超低分子量ヘパリン組成物
US7511026B2 (en)	2003-03-25	2009-03-31	Seikagaku Corporation	Therapeutic agent for nerve damage
AU2004224779A1 (en) *	2003-03-28	2004-10-07	Laboratoires Serono Sa	Use of clusterin for the treatment and/or prevention of peripheral neurological diseases
FR3000746A1 (fr)	2013-01-04	2014-07-11	Centre Nat Rech Scient	Peptide pour son utilisation dans le traitement des neuronopathies motrices
RU2639574C2 (ru) *	2016-05-23	2017-12-21	Алексей Георгиевич Александров	Способ получения низкомолекулярного гепарина

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4608365A (en) *	1984-03-30	1986-08-26	University Of Southern California	Treatment of neurologic functions
JPH04507234A (ja) *	1988-04-22	1992-12-17	ベイラー・カレッジ・オブ・メディスン	筋萎縮性側索硬化症の治療用組成物の製造方法
EP0493533A4 (en) *	1989-10-27	1992-10-28	Case Western Reserve University	Inhibition of cell growth by keratan sulfate, chondroitin sulfate, dermatan sulfate and other glycans
US6258341B1 (en) *	1995-04-14	2001-07-10	Inhale Therapeutic Systems, Inc.	Stable glassy state powder formulations
FR2740686B1 (fr) *	1995-11-03	1998-01-16	Sanofi Sa	Formulation pharmaceutique lyophilisee stable
US6491965B1 (en) *	1995-11-30	2002-12-10	Hamilton Civic Hospitals Research Development, Inc.	Medical device comprising glycosaminoglycan-antithrombin III/heparin cofactor II conjugates
FR2763849B1 (fr) *	1997-05-28	2000-09-15	Rhone Poulenc Rorer Sa	Utilisation des heparines de bas poids moleculaire pour la prevention et le traitement des oedemes cerebraux
US6608042B2 (en) *	2000-03-28	2003-08-19	Aventis Pharma, S.A.	Pharmaceutical compositions containing oligosaccharides, the novel oligosaccharides and preparation thereof

1998
- 1998-12-17 FR FR9815919A patent/FR2787329B1/fr not_active Expired - Lifetime
1999
- 1999-12-13 EP EP99958308A patent/EP1140119B1/de not_active Expired - Lifetime
- 1999-12-13 AU AU15697/00A patent/AU1569700A/en not_active Abandoned
- 1999-12-13 PT PT99958308T patent/PT1140119E/pt unknown
- 1999-12-13 IL IL14327999A patent/IL143279A0/xx active IP Right Grant
- 1999-12-13 WO PCT/FR1999/003109 patent/WO2000035462A1/fr not_active Ceased
- 1999-12-13 AT AT99958308T patent/ATE273711T1/de not_active IP Right Cessation
- 1999-12-13 SI SI9930631T patent/SI1140119T1/xx unknown
- 1999-12-13 JP JP2000587782A patent/JP2002532431A/ja active Pending
- 1999-12-13 DK DK99958308T patent/DK1140119T3/da active
- 1999-12-13 ES ES99958308T patent/ES2222748T3/es not_active Expired - Lifetime
- 1999-12-13 CA CA2354762A patent/CA2354762C/fr not_active Expired - Fee Related
- 1999-12-13 DE DE69919578T patent/DE69919578T2/de not_active Expired - Lifetime
2001
- 2001-05-21 IL IL143279A patent/IL143279A/en not_active IP Right Cessation
- 2001-06-08 NO NO20012849A patent/NO20012849L/no not_active Application Discontinuation
- 2001-06-14 US US09/881,267 patent/US20020040013A1/en not_active Abandoned
2003
- 2003-08-20 US US10/644,109 patent/US20030236222A1/en not_active Abandoned
- 2003-08-20 US US10/644,150 patent/US20040038938A1/en not_active Abandoned
2005
- 2005-12-21 US US11/314,130 patent/US20060100175A1/en not_active Abandoned

Also Published As

Publication number	Publication date
IL143279A0 (en)	2002-04-21
JP2002532431A (ja)	2002-10-02
DE69919578T2 (de)	2005-07-14
EP1140119B1 (de)	2004-08-18
CA2354762C (fr)	2010-02-09
SI1140119T1 (en)	2004-10-31
NO20012849D0 (no)	2001-06-08
FR2787329A1 (fr)	2000-06-23
NO20012849L (no)	2001-06-08
EP1140119A1 (de)	2001-10-10
ATE273711T1 (de)	2004-09-15
US20040038938A1 (en)	2004-02-26
US20030236222A1 (en)	2003-12-25
PT1140119E (pt)	2004-11-30
IL143279A (en)	2006-12-10
DK1140119T3 (da)	2004-12-20
WO2000035462A1 (fr)	2000-06-22
DE69919578D1 (de)	2004-09-23
US20060100175A1 (en)	2006-05-11
FR2787329B1 (fr)	2001-02-09
AU1569700A (en)	2000-07-03
US20020040013A1 (en)	2002-04-04
CA2354762A1 (fr)	2000-06-22

Publication	Publication Date	Title
US6451337B1 (en)	2002-09-17	Chitosan-based nitric oxide donor compositions
JP2018154848A (ja)	2018-10-04	低抗凝固剤ヘパリン
CA2190107A1 (en)	1995-11-23	Compositions for treatment of chronic inflammatory diseases
US10420795B2 (en)	2019-09-24	Pharmaceutical composition for relieving pain
BRPI0406674B1 (pt)	2015-12-22	composição para a ministração intranasal de fentanila ou um seu sal farmaceuticamente aceitável, uso de uma composição, dispositivo para pulverização, e, processo para preparar uma composição
ES2385088T3 (es)	2012-07-18	Uso de derivados de exopolisacáridos (EPS) despolimerizados sulfatados, como cicatrizantes
US20030133986A1 (en)	2003-07-17	Compositions for stabilizing poly (carboxylic acids)
ES2222748T3 (es)	2005-02-01	Utilizacion de heparinas de bajo peso molecular para la prevencion y/o el tratamiento de enfermedades motoneuronales.
ES2237425T3 (es)	2005-08-01	Uso de glucosaminoglicanos en el tratamiento de la demencia senil.
JPWO2004084912A1 (ja)	2006-06-29	神経障害処置剤
JPH10506884A (ja)	1998-07-07	マクロファージ浸潤に関連する病気あるいは容体、特に脳卒中、心筋梗塞の治療
ES2236206T3 (es)	2005-07-16	Composiciones farmaceuticas que contienen oligosacaridos y su preparacion.
ES2200569T3 (es)	2004-03-01	Nueva aplicacion terapeutica de la nicergolina.
TW546141B (en)	2003-08-11	Low-molecular-weight heparins for use in the treatment of cerebral oedemas
KR100531721B1 (ko)	2005-11-28	중추 신경계 외상 예방과 치료를 위한 저분자량 헤파린의사용
ES2201802T3 (es)	2004-03-16	Nuevo uso terapeutico de 1,6-dimetil-8-beta-hidroximetil-10 alfa-metoxiergolina.
JP2004002369A (ja)	2004-01-08	医薬組成物
JP2019064996A (ja)	2019-04-25	嗅覚機能を改善する医薬組成物
ES2245651T3 (es)	2006-01-16	Asociacion de lumilisergol y riluzol para la profilaxis y/o el tratamiento de enfermedades motoneuronales.